Abstract
Serious bacterial infections occur frequently in patients with cancer, both as a result of their underlying disease and its treatment. Several factors increase the risk of bacterial infections, the foremost of which is neutropenia (absolute neutrophil count [ANC] ≤500 cells/mm3). Neutropenia, however, seldom occurs alone, but is often superimposed on other risk factors, such as impaired humoral or cellular immunity, the presence of foreign medical devices, surgery, radiation, and poor nutrition. Other factors that influence the frequency and spectrum of bacterial infection include the use of antimicrobial prophylaxis, the intensity and nature of chemotherapy, and local institutional epidemiology. This chapter will focus on the management of bacterial infections in cancer patients, including infection prevention, treatment, infection control, and antimicrobial stewardship.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ANC:
-
Absolute neutrophil count
- ESBL:
-
Extended-spectrum ß-Lactamases
- KPC:
-
Klebsiella pneumoniae carbapenemase
- MASCC:
-
Multinational Association for Supportive Care in Cancer
- MRSA:
-
Methicillin-resistant Staphylococcus aureus
- VRE:
-
Vancomycin-resistant enterococci
References
Agwu A, Lee CKK, Jain SK et al (2008) A worldwide web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 47:747–753
Baden LR (2005) Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353:1052–1054
Barton DPJ, Fiorica JV, Hoffman MS et al (1993) Cervical cancer and tubo-ovarian abscesses: a report of three cases. J Reprod Med 38:562–564
Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340
Bodey GP, Fainstein V, Elting LS et al (1990) Beta-lactam regimens for the febrile neutropenic patient. Cancer 65:9–16
Brooker DE, Savage JE, Twiggs LB et al (1987) Infectious morbidity in gynecologic cancer. Am J Obstet Gynecol 156:515–520
Chamilos G, Bamias A, Efstathiou E et al (2005) Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103:2629–2635
Corey L, Boeckh M (2002) Persistent fever in patients with neutropenia. N Engl J Med 346:222–224
Dellit TH, Owens RC, McGowan JE et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177
Elting LS, Bodey GP, Fainstein V (1986) Polymicrobial septicemia in the cancer patient. Medicine 65:218–225
Elting LS, Rubenstein EB, Rolston KV et al (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25(2):247–259
Elting LS, Rubenstein EB, Rolston K et al (2000) Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 8:3699–3706
Freifeld A, Marchigiani D, Walsh T et al (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311
Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93
Gafter-Gvili A, Fraser A, Paul M et al (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995
Hübel K, Carter RA, Liles WC et al (2002) Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 42:1414–1421
Hughes WT, Armstrong D, Bodey GP et al (1997) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25(3):551–573
Imachi M, Tanaka S, Ishikawa S et al (1993) Spontaneous perforation of pyometra presenting as generalized peritonitis in a patient with cervical cancer. Gynecol Oncol 50:384–388
Kern KV (2006) Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 15:533–540
Kern WV, Andriof E, Oethinger M et al (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681–687
Kern WV, Cometta A, De Bock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341:312–318
Klastersky J, Paesmans M, Rubenstein E et al (2000) The MASCC risk index: a multinational scoring system to predict low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051
Lyman GH, Rolston KV (2010) How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract 6(3):149–152
Metjian TA, Prasad PA, Kogon A et al (2008) Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J 27:106–111
Mulanovich V, Chemaly R, Mihu C et al (2009) Antimicrobial stewardship program in The Critical Care Unit (CCU) of a comprehensive cancer center (Abst. 09–070). In: Multinational Association for supportive care in cancer 2009 international MASCC/ISOO symposium, Rome
Penel N, Yazdanpanah Y, Chauvet MP et al (2007) Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. J Surg Oncol 96(2):124–129
Rolston KVI (2001) Infections in patients with solid tumors. In: Rolston KVI, Rubenstein E (eds) Textbook of febrile neutropenia. Martin Dunitz Ltd, London
Rolston KVI (2003) Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever. Cancer Treat Rev 29:551–554
Rolston KV (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(4):246–252
Rolston KVI, Bodey GP (1993) Diagnosis and management of perianal and perirectal infection in the granulocytopenic patient. In: Remington J, Swartz MN (eds) Current clinical topics in infectious diseases. Blackwell Scientific Publications, Boston
Rolston KVI, Dholakia N, Rodriguez S et al (1995) Nature and outcome of febrile episodes in patients with pancreatic and hepato-biliary cancer. Support Care Cancer 3:414–417
Rolston KVI, Manzullo EF, Elting LS et al (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia. Cancer 106:2489–2494
Rolston KVI, Bodey GP, Safdar A (2007) Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 45:228–233
Rolston KVI, Frisbee-Hume SE, Patel S et al (2009) Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18(1):89–94
Rubenstein EB, Rolston K, Benjamin RS et al (1993) Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer 71:3640–3646
Safdar A, Rolston KV (2007) Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 45:1602–1609
Smith TH, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205
Statistics published by the American Cancer Society (2010) Cancer facts figures. www.cancer.org/Research/Cancer
Vidal L, Paul M, Ben-Dor I et al (2004) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 54:29–37
Walton GM (1999) Complications of percutaneous gastronomy in patients with head and neck cancer – an analysis of 42 consecutive patients. Ann R Coll Surg Engl 81:272–276
Wisplinghoff H, Seifert H, Wenzel RP et al (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110
Yadegarynia D, Tarrand J, Raad I (2003) Current spectrum of bacterial infections in cancer patients. Clin Infect Dis 37:1144–1145
Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Rolston, K.V.I. (2012). Management of Bacterial Infectious Complications in Cancer Patients. In: Khan, A. (eds) Bacteria and Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2585-0_12
Download citation
DOI: https://doi.org/10.1007/978-94-007-2585-0_12
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2584-3
Online ISBN: 978-94-007-2585-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)